Shareholder Alert: Robbins LLP Reminds Investors AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that engages in developing antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio's lead drug candidate is etokimab, which treats various inflammatory diseases.If you suffered a loss as a result of AnaptysBio's misconduct, click here.AnaptysBio, Inc. (ANAB) Accused of Misleading Shareholders According to the complaint, in October 2017, AnaptysBio touted "positive" data from its phase 2a clinical trial of etokimab, stating it provided "a solid foundation for the continued development of [etokimab] across a number of atopic diseases" and that the drug's efficacy was "very encourag[ing]." However, on March 2
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.MarketBeat
- AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]Yahoo! Finance
- Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 5/9/24 - Miss
ANAB
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/6/24 - Form SC
- ANAB's page on the SEC website